The 2-Minute Rule for QST4
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage many intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo targets have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individua